Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 18;7(9):e937. doi: 10.1097/HS9.0000000000000937

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

PMC Copyright notice

Figure 2. — Strategies to acquire control over the cytokine release of CAR-T cells. (A) mRNA electroporation, a nonviral transduction method resulting in CAR-T cells with transient activity to limit the risk of persistent toxicity. (B) ADCC or CDC of CAR-T cells containing a truncated CD20 (CD20t) or EGFRt molecule. (C) Suicide gene system consisting of iCasp9 activation after the administration of a CID, which will dimerize caspase 9 and subsequently activate the downstream executioner caspase 3, resulting in apoptosis of the CAR-T cell. (D) A temporary switch-off system using dasatinib to inhibit the phosphorylation of LCK, a key regulator for T-cell signaling. Created with BioRender.com. ADCC = antibody-dependent cellular cytotoxicity; CAR = chimeric antigen receptor; CDC = complement-dependent cytotoxicity; CID = chemical inducer of dimerization; EGFRt = epidermal growth factor receptor; iCasp9 = inducible caspase 9; LCK = lymphocyte-specific protein tyrosine kinase.